肝动脉介入联合靶向治疗结肠癌肝转移80例临床研究

Clinical research on hepatic artery intervention combining targeted therapy on 80 patients with hepatic metastasis of colonic carcinoma

目的研究肝动脉介入治疗联合靶向治疗结肠癌肝转移的临床效果及不良反应。方法选取我院的80例结肠癌肝转移患者,按照治疗方法的不同,对照组给予肝动脉介入治疗,观察组在对照组的基础上给予靶向治疗,观察两组患者的临床效果及不良反应。结果两组患者治疗后的总有效率比较(χ2=6.9520,P=0.0084),1年生存率比较(χ2=4.7760,P=0.0289),2年生存率比较(χ2=5.6144,P=0.0178),3年生存率比较(χ2=4.3988,P=0.0360),5年生存率比较(χ2=4.4443,P=0.0350),差异具有统计学意义。两组患者在不良反应比较上无显著差异。结论肝动脉介入治疗联合靶向治疗结肠癌肝转移,效果较好,显著延长患者的寿命,值得临床推广使用。

Objective To study clinical effects and adverse reactions of hepatic artery intervention combining targeted therapy on hepatic metastasis of colonic carcinoma. Methods Eighty cases of patients with hepatic metastasis of colonic carcinoma, patients in the control group were selected, patients in the control group were subject to hepatic artery in-tervention therapy according to different methods of treatment , and patients in the observation group were subject to targeted therapy on the basis of that applied to patients in the control group , clinical effects and adverse reactions of patients in two groups were observed. Results The comparison in the total effective rate of patients in two groups （χ2=6.9520,P=0.0084）, and the comparison in one-year survival rate of patients in two groups（χ2=4.7760,P=0.0289）, the comparison in two-year survival rate of patients in two groups （χ2=5.6144,P=0.0178）, the comparison in three-year survival rate of patients in two groups（χ2=4.3988,P=0.0360）, and the comparison in five-year survival rate of patients in two groups （χ2=4.4443,P=0.0350）, the differences were statistically significant. The comparison in adverse reaction of patients in two groups was not significantly different. Conclusion The hepatic artery intervention combining targeted therapy on hepatic metastasis of colonic carcinoma delivers great effect and significantly prolong the life of patients , being worthy of clinical application.